Halozyme Therapeutics, Inc. (NasdaqGS:HALO) announces a share repurchase program. Under the program, the company will repurchase up to $750 million worth of its outstanding common stock.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.57 USD | +0.29% | -0.18% | +4.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.36% | 4.9B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.